aBiofilm: a resource of anti-biofilm agents and their potential implications in targeting antibiotic drug resistance

Akanksha Rajput, Anamika Thakur, Shivangi Sharma and Manoj Kumar

Bioinformatics Centre, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39-A, Chandigarh 160036, India

Received August 17, 2017; Revised October 15, 2017; Editorial Decision October 30, 2017; Accepted November 07, 2017

ABSTRACT

Biofilms play an important role in the antibiotic drug resistance, which is threatening public health globally. Almost, all microbes mimic multicellular lifestyle to form biofilm by undergoing phenotypic changes to adapt adverse environmental conditions. Many anti-biofilm agents have been experimentally validated to disrupt the biofilms during last three decades. To organize this data, we developed the ‘aBiofilm’ resource (http://bioinfo.imtech.res.in/manojk/abiofilm/) that harbors a database, a predictor, and the data visualization modules. The database contains biological, chemical, and structural details of 5027 anti-biofilm agents (1720 unique) reported from 1988–2017. These agents target over 140 organisms including Gram-negative, Gram-positive bacteria, and fungus. They are mainly chemicals, peptides, phages, secondary metabolites, antibodies, nanoparticles and extracts. They show the diverse mode of actions by attacking mainly signaling molecules, biofilm matrix, genes, extracellular polymeric substances, and many more. The QSAR based predictor identifies the anti-biofilm potential of an unknown chemical with an accuracy of ~80.00%. The data visualization section summarized the biofilm stages targeted (Circos plot); interaction maps (Cytoscape) and chemicals diversification (CheS-Mapper) of the agents. This comprehensive platform would help the researchers to understand the multilevel communication in the microbial consortium. It may aid in developing anti-biofilm therapeutics to deal with antibiotic drug resistance menace.

INTRODUCTION

Biofilms are the assembled colony of microbes encapsulated with self-secreted cocoon (1,2). These are the major survival strategy adapted by almost all bacterial species against severe environments (3). In biofilms, unicellular bacteria mimic multicellular behavior by division of labor and cell-to-cell communication (4). Historically, Van Leeuwenhoek first detected microbial colonies from tooth surface using a simple microscope in 1676 (5). Later, Costerton et al. in 1978 coined the term ‘biofilm’ for the colonial form of bacteria (6). The biofilms formed on living or nonliving like human body, plants, medical devices, rocks, etc. (7–9). The main constituent of a biofilm is the extracellular polymeric substances (EPS). This EPS matrix comprised of polysaccharides, proteins, extracellular DNA, lipids etc and its composition varies according to growth conditions, substrates, medium, and species (10).

The microbial colonization is either mono or polyspecies and driven through signaling molecules (11,12). For example, autoinducer-2 helps to develop the oral biofilms formed by Streptococcus gordonii, Porphyromonas gingivalis (11); and acyl homoserine lactones assist the growth of Pseudomonas aeruginosa and Burkholderia cepacia microcolonies (13). Similarly, competence stimulating peptides contribute in the biofilm formation of Streptococcus mutans (14); and tyrosol aids colonization among Candida albicans (15). Simultaneously, these microcolonies are difficult targets for the antibiotics to inhibit that pathogen.

Currently, drug resistance is the major crisis before scientific community in infectious diseases according to World Health Organization (WHO) report (http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/) (16). In biofilms, the bacteria display 10–1000-fold increase in antibiotic resistance. It happens because of the specialized features like efflux pumps, modifying enzymes, evading the immune system and target mutations (17–20). Sakhtah et al. in 2016 proved the role of multidrug efflux pump (MexGHI-OpmD) through a natural phenazine in the biofilm development of P. aeruginosa, an opportunistic
pathogen (21). The pathogenicity of the facultative anaerobe *Vibrio cholerae* increased due the biofilm formation in the environment as well as during outbreaks (22). Similarly, switching to biofilm form increases the persistence of *C. albicans* during mucosal to systemic infection (23). The exoproteins of the biofilm EPS matrix corroborated as multivalent vaccine candidate against biofilm-associated chronic infections of *Staphylococcus aureus* (24). However, stubborn nature of biofilms helps the pathogens to overcome the host innate response as well as antibiotics (25).

Many studies (1988-till date) reported the experimental testing of anti-biofilm agents against different microorganisms. These anti-biofilm agents have varied actions like targeting the quorum sensing (QS) signaling molecules (26), EPS matrix (27,28), genes involved in biofilm formation and adhesion (29) etc. The anti-biofilm agents verified as adjuvants or alternatives to conventional antibiotic treatments. Simultaneously, they also act synergistically with antibiotics and improve their inhibitory action against chronic infections (30).

The biofilm’s universal distribution, varied composition, virulence and resistance towards antibiotics make them among one of the highly explored field. Since, there is no platform available to understand the diversified anti-biofilm agents; therefore, we developed the first comprehensive resource ‘aBiofilm’ in this concern. It harbors biological, chemical and structural details of 5027 entries belonged to varied anti-biofilm agents. It contains a database, a predictor (qualitative), and the data visualization modules.

**MATERIALS AND METHODS**

**aBiofilm resource structure**

The aBiofilm has three sub-categories namely a database, a predictor, and the data visualization. The database covers the chemical, biological, and structural information of anti-biofilm agents. Using curated anti-biofilm chemicals, we developed a Quantitative structure–activity relationship (QSAR) based predictor employing the Support Vector Machine (SVM), a machine learning technique. Further, we also carried out diverse analyses to better understand the anti-biofilm agents. The ‘aBiofilm’ architecture is available in the Supplementary Figure S1.

**Database**

**Data acquisition and curation.** We performed an intensive literature search to extract the relevant information about anti-biofilm agents for developing a database. We scanned the PubMed using a query (by combining suitable keywords and Boolean operators) to fetch the relevant articles:

```
((biofilm) AND (inhibit OR antagonist OR interference OR modulator OR quench))
```

The query resulted in ~7500 articles till 15 September 2017 spread over last three decades. After the early screening, we filtered ~3500 articles that may contain the data of biofilm inhibitors (excluding reviews and non-potential articles). Finally, the aBiofilm database composes the manually curated agents from 526 articles having the needed information. Finally, 5027 entries belonged to 1720 unique anti-biofilm agents targeting as many as 140 microorganisms with an average discovery rate of ~167 entries and ~57 unique anti-biofilm agents yearly.

**Database organization.** The records in the aBiofilm database include the biological, chemical and structural information. The biological details include the fields like anti-biofilm agents, type of anti-biofilm agents, organism/strain targeted, concentration of agent, percentage (%) inhibition. In addition, it also has the stage of biofilm targeted, mechanism of action, media and apparatus used to detect the biofilm inhibition, etc. Since the percentage inhibition was not directly provided in the maximum articles, therefore we calculated it using the absorbance readings by the following formula (31,32):

\[
\% \text{ Inhibition} = \frac{\text{OD}_{\text{control}} - \text{OD}_{\text{experimental}}}{\text{OD}_{\text{control}}} \times 100
\]

where OD (control) is the optical density of a control and OD (experimental) is the optical density of an experimental setup.

We manually extracted the chemical information from various chemical repositories like PubChem (https://pubchem.ncbi.nlm.nih.gov), ChemSpider (http://www.chemspider.com/) and chemicalize (https://chemicalize.com/) (33,34). The chemical details include International Union of Pure and Applied Chemistry (IUPAC name), simplified molecular-input-line-entry system (SMILES), Molecular formula, Molecular weight, IUPAC International Chemical Identifier (InCHI) and Lipinski rule for five. The structural details include the 2-dimensional and 3-dimensional view of each chemical. We manually sketched the compounds using chemicalize module available in ChemAxon package. Further, we calculated the chemical properties and the structure (.sdf format) of each chemical. Last, displaying the agents on the web server was accomplished through the mol2ps (http://merian.pch.univie.ac/~nhaider/cheminf/mol2ps.html) and JavaScript-Based Molecular Viewer (JSmol) from Jmol (http://jmol.sourceforge.net/).

**Predictor.** In our database, there are 896 unique anti-biofilm agents (chemicals) with SMILES and defined inhibition efficiencies either low to high or 0–100%. We need a positive and a negative data sets to develop a classifier for predicting the biofilm inhibition efficiency of any compound. We found that in the literature >60% and <20% biofilm inhibition were considered ‘high’ and ‘low’ respectively for these extracted chemicals. Therefore, we have selected experimentally confirmed 492 chemicals with high (>60%) and low (<20%) inhibition efficiency as positive (271) and negative (221) datasets respectively for the classification based SVM model development. For a better classifier, we have not included the chemicals having moderate efficiency (35). We subdivided the 492 chemicals into T^450 training/testing and V^45 independent/validation datasets using a randomization method. This procedure was repeated in triplicates and all datasets performed equally well. Therefore, for the model development, we opted one of these random datasets.

First, we fetched the descriptors of all the chemicals using PaDEL software (36,37) that led to the 15352 sized vec-
tor. Further, the most contributing 40 features were selected using two filters, i.e. ‘Remove Useless’ available in Weka package (38) followed by minimum redundancy and maximum relevance (mRMR) algorithm (39). The SVM technique was used for the model development employing 10-fold cross validation (40). We evaluated the developed models using sensitivity, specificity, accuracy, Matthews correlation coefficient (MCC) and receiver operating characteristic (ROC) (35,40). Similarly, the robustness of the developed model was checked through independent/validation dataset. We provided the flowchart depicting the methodology of the predictor development in Supplementary Figure S2.

Analyzes and data visualization. In the aBiofilm, we did three types of analyses to explore the anti-biofilm agents. First, we analyzed the data for highlighting the biofilm stages of the microbes targeted by different agents using CIRCOS software (41,42). Second, the interrelationship between four important fields of the database was highlighted i.e. the anti-biofilm agent acting on the particular stage of the biofilm of a microorganism through interaction network by Cytoscape software (43). Third, we evaluated the diversity of anti-biofilm chemicals using chemical clustering through k-means clustering method available in ChessMapper (44). We provided these analyses on the webservice under ‘analyses’ menu.

Web server implementation. The aBiofilm web server was designed using LAMP software bundle (35,45,46). It uses Linux as the operating system; Apache for the web server; MySQL as the relational database management system and PHP (occasionally Perl or Python) as an object-oriented scripting language. The front-end of the web server was developed using scripting languages like HTML, CSS, XML, Javascript, etc. Similarly, we used PHP, MySQL, Perl, Python, in the back-end to make the server functional.

RESULT AND DISCUSSION

Database

Database statistics. Currently, the aBiofilm database harbors 5027 anti-biofilm agents (1720 unique) from 526 articles. Among the topmost anti-biofilm agents, we found 3-(4-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one has 86 entries. Followed by 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 3-(4-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 5-Fluorouracil; AHL lactonases; Norspermidine with 79; 79; 79; 58; 46 and 41 records respectively. The aBiofilm database statistics. Currently, the aBiofilm database harbors 5027 anti-biofilm agents (1720 unique) from 526 articles. Among the topmost anti-biofilm agents, we found 3-(4-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one has 86 entries. Followed by 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 3-(4-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 5-Fluorouracil; AHL lactonases; Norspermidine with 79; 79; 79; 58; 46 and 41 records respectively.

Figures 1A and 1B: Diagrammatic representation of the topmost anti-biofilm agents in aBiofilm resource. (A) topmost anti-biofilm agents in aBiofilm resource. (B) top-10 organism targeted with anti-biofilm agents available in aBiofilm resource.

We have also included a ‘Search’ tool to fetch the needed information according to user’s requirement. User can enter the query for searching in all the fields, or any specific fields like anti-biofilm ID, anti-biofilm agent, SMILES, anti-biofilm agent type, targeted organism, preliminary assay, and journal names. User can click any of the six choices to display list of unique entries and the frequency. User will get an interactive tabular output of any sub categories displaying the important fields. It includes anti-biofilm ID hyperlinked to details of individual entry and anti-biofilm agent linked to an external chemical repository. Other fields are molecular formula of anti-biofilm agents, agent type, targeted organism (linked to NCBI-taxonomy browser), strain, inhibition efficiency, biofilm stages, growth media and reference PMID (hyperlinked to PubMed). Each anti-biofilm ID linked to the detailed biological, chemical, and structural information. The Supplementary Figure S4 has depicted the use of ‘browse’.

Data retrieval. We have integrated the ‘Browse’ to explore and retrieve the overall data through six major fields, i.e. anti-biofilm agents, types of anti-biofilm agents, targeted organism, types of organism, preliminary assay, and journal names. User can click any of the six choices to display list of unique entries and the frequency. User will get an interactive tabular output of any sub categories displaying the important fields. It includes anti-biofilm ID hyperlinked to details of individual entry and anti-biofilm agent linked to an external chemical repository. Other fields are molecular formula of anti-biofilm agents, agent type, targeted organism (linked to NCBI-taxonomy browser), strain, inhibition efficiency, biofilm stages, growth media and reference PMID (hyperlinked to PubMed). Each anti-biofilm ID linked to the detailed biological, chemical, and structural information. The Supplementary Figure S4 has depicted the use of ‘browse’.

We have also included a ‘Search’ tool to fetch the needed information according to user’s requirement. User can enter the query for searching in all the fields, or any specific fields like anti-biofilm ID, anti-biofilm agent, SMILES, anti-biofilm agent type, targeted organism, preliminary assay, and PubMed ID. The search will display ten fields as provided in the browse choice. Further, detailed individual
Figure 2. CIRCOS plot showing the information of stages of the biofilm among the organism targeted with anti-biofilm agents. CIRCOS plot divided into two parts. Rightmost part showed the organisms targeted through anti-biofilm agents while leftmost part represented the stages of the organism affected with anti-biofilm agents. The band color of the rightmost part is depicted in five different colors viz. yellow (Fungus), purple (Gram-negative bacteria), black (Gram-positive bacteria), orange (Gram variable bacteria), and dark gray (a mixed culture of bacteria and/or fungus). Whereas, leftmost part and rays (links) of circos is divided into five different colors according to the stages like light green (Pre-formation), blue (Adhesion), red (Formation), orange (Maturation), and green (Pre-formed).
web page of the entry is available by clicking on any anti-biofilm ID.

**Predictor.** We have developed a QSAR based predictor for the estimation of the inhibition efficiency of any chemicals against biofilm. During 10-fold cross-validation on T450 dataset, the predictive model achieved the sensitivity, specificity, accuracy, MCC, and ROC of 77.92%, 80.77%, 79.18%, 0.58 and 0.83 respectively. Similarly, the developed model performed equally well on the independent/validation dataset (V42) with sensitivity, specificity, accuracy, MCC, and ROC of 86.36%, 75.00%, 80.95%, 0.62 and 0.88 correspondingly. We have also given the experimental and predicted anti-biofilm efficiency of the independent/validation dataset (V42) for comparison in the Supplementary Table S1. It suggested good correlation between the experimental and the predicted anti-biofilm activity. A user can provide the input chemical in the form of SMILES/sdf/mol format for predicting the anti-biofilm potential. Further, a user can also draw the query chemical in the integrated JSME window (47). The output is displayed in a tabular format including query SMILES, predicted anti-biofilm efficacy (low or high) with a color gradient, 2D (with marked stereochemistry) and 3D structure, and a few drug-likeness properties. Beside, we are also checking the query compound in ‘aBiofilm’ database and displayed the available chemicals including experimental efficiency and other details.

**Analyses and data visualization.** We performed biofilm stages analysis using CIRCOS plot by highlighting three important fields of the database namely organism, its group and stages of the biofilm targeted (Figure 2). The CIRCOS plot has two parts namely organisms and stages of biofilms. One hundred forty unique organisms further classified into five different groups and connected to the stages targeted by the anti-biofilm agents. The plot showed biofilms of maximum microbes including bacteria (both Gram-positive and Gram-negative) and fungus targeted at the formation stage e.g. *Burkholderia* spp., *Candida* spp., *Staphylococcus* spp., and many more. Further, some of the pathogenic bacteria like *P. aeruginosa*, *C. albicans*, *E. coli*, *S. aureus*, etc. aimed for more than one stages like adhesion, formation, maturation and pre-formed. We used cytoscape software based interaction maps to represent the four important fields of the aBiofilm database i.e. anti-biofilm agents, inhibition efficiency, stage of biofilm in the targeted organism. The interaction map displayed some important pathogens like ESKAPE (*Enterococcus faecium*, *S. aureus*, *Klebsiella pneumoniae*, *A. baumannii*, *P. aeruginosa* and *Enterobacter* species) and non-ESKAPE (top-10). For example, for the two stages of biofilm (formation and pre-formed) of the *K. pneumoniae* targeted by eighteen different anti-biofilm agents namely phenanthrene, norspermidine, myristic acid, cyanidine, etc. with high and medium inhibition efficiency (Figure 3). All the prokaryotic (Gram-positive and Gram-negative bacteria) and eukaryotic (fungus or yeast) microbes undergoes biofilm mode of growth. Remarkably, the biofilm development in the ESKAPE pathogens is the primary cause of nosocomial infections worldwide (48). Various anti-biofilm agents developed against ESKAPE and non-ESKAPE pathogens like *S. aureus* (49), *P. aeruginosa* (50), *C. albicans* (51), *E. faecalis* (52) and many more included in our database. These pathogens targeted at single or multiple stages of biofilm formation like adhesion (49), maturation (53), pre-formed (54), etc.

We carried out Chemical Spacing analysis to check the chemical diversity of the anti-biofilm agents (Supplementary Figure S5). Clustering represented as a concentric circle in which, the core shows the embedded chemicals in 3D space and highlighting the superimposed structure of each cluster. While the outer circle showed the zoomed view of each cluster called the maximum common subgraph (MCS). The chemical clustering is providing the information of a total number of the chemicals in every cluster with Pearson’s correlation coefficient (0.93) of the embedding. The anti-biofilm agents present wide-ranging chemical diversity and MCS. They consist of aliphatic core backbone namely propane, pentane, and 2-amino-1-(2-methylpyrrolidin-1-yl)propan-1-one which target important biofilm stages like formation, and pre-formed in the pathogens like *P. aeruginosa*, *C. albicans*, *S. aureus*. 

---

**Figure 3.** Interaction map of *Klebsiella pneumoniae* showing the inter-relationship between anti-biofilm agents, inhibition efficacy and stage of organism targeted. Green colored box showing targeted organism, pink colored box means the stage of biofilm, blue boxes depicts anti-biofilm agents, and yellow box signifies the targeting efficiency.
CONCLUSION
Antibiotic drug resistance threat aggravated because of the faster rate of the resistance development in the microbial community. Relatively the discovery of novel antibiotics is slow (55). Intriguingly, biofilm adaptation among the microbes is one of the leading causes of antibiotic resistance (56,57). Therefore, aBiofilm would be very helpful to the researchers struggling to develop effective and broad-spectrum anti-biofilm agents. This is the first resource having all types of anti-biofilm agents reported in literature, i.e. chemicals, phytochemicals, amino acids, antibiotics, peptides, antibody, phages and many more. We are providing the platform for chemical, biological and structural information of anti-biofilm agent from three decades. The researchers can pick up the extensive information of single and multi-species biofilm targeting agents. Beside, a general predictor can identify the anti-biofilm activity of any chemical. However, this tool has limit in predicting organism/strain specific anti-biofilm activity. Varied data visualization support the users by exploring the mechanism and diversity of the anti-biofilm agents. Last, this would aid the researchers to understand, explore, and design novel and effective biofilm targeting approaches and would further intensify the research on biofilm specifically to tackle the menace of drug resistance.

AVAILABILITY
The aBiofilm resource is an open access web server and available at http://bioinfo.imtech.res.in/manojk/abiofilm/. We will update the resource regularly at half yearly or when enough data is available.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.

FUNDING
Department of Biotechnology, Government of India [GAP0001]; CSIR-Institute of Microbial Technology. Funding for open access charge: CSIR-Institute of Microbial Technology.

Conflict of interest statement. None declared.

REFERENCES
1. Donlan, R. M. (2002) Biofilms: microbial life on surfaces. Emerg. Infect. Dis., 8, 881–890.
2. Hall-Stoodley, L., Costerton, J. W. and Stoodley, P. (2004) Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol., 2, 95–108.
3. Dunne, W. M. Jr (2002) Bacterial adhesion: seen any good biofilms lately? Clin. Microbiol. Rev., 15, 155–166.
4. Pandin, C., Le Coq, D., Canette, A., Aymerich, S. and Briandet, R. (2017) Should the biofilm mode of life be taken into consideration for microbial biocontrol agents? Microb. Biotechnol., 10, 719–734.
5. Donlan, R. M. and Costerton, J. W. (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev., 15, 167–193.
6. Costerton, J. W., Geesey, G. G. and Cheng, K. J. (1978) How bacteria stick. Sci. Am., 238, 86–95.
7. Gorbushina, A. A. (2007) Life on the rocks. Environ. Microbiol., 9, 1613–1631.
8. Walker, J. J., Spear, J. R. and Pacic, N. R. (2005) Geobiology of a microbial endolithic community in the Yellowstone geothermal environment. Nature, 434, 1011–1014.
9. Lopez, D., Vlamakis, H. and Kolter, R. (2010) Biofilms. Cold Spring Harb. Perspect. Biol., 2, a000398.
10. Monds, R. D. and O’Toole, G. A. (2009) The developmental model of microbial biofilms: ten years of a paradigm up for review. Trends Microbiol., 17, 73–87.
11. Federle, M. J. and Bassler, B. L. (2003) Interspecies communication in bacteria. J. Clin. Invest., 112, 1291–1299.
12. Rajput, A. and Kumar, M. (2017) In silico analyses of conservational, functional and phylogenetic distribution of the LuxI and LuxR homologs in Gram-positive bacteria. Sci. Rep., 7, 6969.
13. Huber, B., Riedel, K., Hentzer, M., Heydorn, A., Gotschlich, A., Givskov, M., Molin, S. and Eberl, L. (2001) The cep quorum-sensing system of Burkholderia cepacia H111 controls biofilm formation and swarming motility. Microbiology, 147, 2517–2528.
14. Li, Y., Lau, P.-C., Tang, N., Svensater, G., Ellen, R. P. and Cvitkovitch, D. G. (2002) Novel two-component regulatory system involved in biofilm formation and acid resistance in Streptococcus mutans. J. Bacteriol., 184, 6333–6342.
15. Ramage, G., Mowat, E., Jones, B., Williams, C. and Lopez-Ribot, J. (2009) Our current understanding of fungal biofilms. Crit. Rev. Microbiol., 35, 340–355.
16. Forslund, K., Sunagawa, S., Kultima, J. R., Mende, D. R., Arumugam, M., Typas, A. and Bork, P. (2013) Country-specific antibiotic use practices impact the human gut resistome. Genome Res., 23, 1163–1169.
17. Walsh, C. (2000) Molecular mechanisms that confer antibacterial drug resistance. Nature, 406, 775–781.
18. Stewart, P. S. and Costerton, J. W. (2001) Antibiotic resistance of bacteria in biofilms. Lancet, 358, 135–138.
19. Rolleides, E., Simitisopoulou, M., Katragkou, A. and Walsh, T. J. (2015) How Biofilms Evade Host Defenses. Microbiol. Spectr., 3, doi:10.1128/microbiolspec.MB-0012-2014.
20. Pletzer, D. and Hancock, R. E. (2016) Antibiofilm Peptides: Potential as Broad-Spectrum Agents. J. Bacteriol., 198, 2572–2578.
21. Sakthi, H., Koyama, L., Zhang, Y., Morales, D. K., Fields, B. L., Price-Whelan, A., Hogan, D. A., Sheppard, K. and Dietrich, L. E. (2016) The Pseudomonas aeruginosa efflux pump MexGHIPopM transports a natural phenazine that controls gene expression and biofilm development. Proc. Natl. Acad. Sci. U.S.A., 113, E3538–E3547.
22. Fong, J. C., Syed, K. A., Klose, K. E. and Yildiz, F. H. (2010) Role of Vibrio polysaccharide (vps) genes in VPS production, biofilm formation and Vibrio cholerae pathogenesis. Microbiology, 156, 2757–2769.
23. Tsui, C., Kong, E. F. and Jabara-Rizk, M. A. (2016) Pathogenesis of Candida albicans biofilm. Pathog. Dis., 74, ftw018.
24. Gil, C., Solano, C., Burgui, S., Matasa, C., Garcia, B., Toledo-Arana, A., Lasal, J. and Valle, J. (2014) Biofilm matrix exoproteins induce a protective immune response against Staphylococcus aureus biofilm infection. Infect. Immun., 82, 1017–1029.
25. Begun, J., Saiami, J. M., Rohde, H., Mack, D., Calderwood, S. B., Ausubel, F. M. and Sifri, C. D. (2007) Staphylococcal biofilm exopolysaccharide protects against Caenorhabditis elegans immune defenses. PLoS Pathog., 3, e57.
26. Bakkikaraj, D., Sivasankar, C. and Pandian, S. K. (2012) Inhibition of quorum sensing regulated biofilm formation in Serratia marcescens causing nosocomial infections. Bioorg. Med. Chem. Lett., 22, 3089–3094.
27. Hentzer, M., Riedel, K., Rasmussen, T. B., Heydorn, A., Andersen, J. B., Parsek, M. R., Rice, S. A., Eberl, L., Molin, S., Hoiby, N. et al. (2002) Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology, 148, 87–102.
28. Kaia, M., Yadav, V. K., Singh, P. K., Sharma, D., Pandey, H., Narvi, S. S. and Agarwal, V. (2015) Effect of cinnamon oil on quorum sensing-controlled virulence factors and biofilm formation in Pseudomonas aeruginosa. PLoS One, 10, e0135495.
29. Ouyang, J., Sun, F., Feng, W., Sun, Y., Qiu, X., Xiong, L., Liu, Y. and Chen, Y. (2016) Quercetin is an effective inhibitor of quorum sensing, biofilm formation and virulence factors in Pseudomonas aeruginosa. J. Appl. Microbiol., 120, 966–974.
30. Wu, H., Song, Z., Hentzer, M., Andersen, J.B., Molin, S., Givskov, M. and Hoiby, N. (2004) Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother., 53, 1054–1061.
31. Costa, E., Silva, S., Tavares, F. and Pintado, M. (2014) Antimicrobial and antibiotic activity of chitosan on the oral pathogen Candida albicans. Pathogens, 3, 908–919.
32. Das, M.C., Sahu, P., Gupta, P., Radhakrishnan, P., De, U.C., Tribedi, P., Akther, Y. and Bhattacharjee, S. (2016) Attenuation of Pseudomonas aeruginosa biofilm formation by Vitexin: a combinatorial study with azithromycin and gentamicin. Sci. Rep., 6, 23347.
33. Rajput, A., Kaur, K. and Kumar, M. (2016) SigMol: repertoire of quorum sensing signaling molecules in prokaryotes. Nucleic Acids Res., 44, D634–D639.
34. Wyenardele, E., Bronselaer, A., Nielen, J., D’Hondt, M., Stalmans, S., Bracke, N., Verbeke, F., Van De Wiele, C., De Tre, G. and De Spiegeleer, B. (2013) Quorumpeps database: chemical space, microbial origin and functionality of quorum sensing peptides. Nucleic Acids Res., 41, D655–D659.
35. Thakur, N., Qureshi, A. and Kumar, M. (2012) AVPpred: collection and prediction of highly effective antiviral peptides. Nucleic Acids Res., 40, W199–W204.
36. Yap, C.W. (2011) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J. Comput. Chem., 32, 1466–1474.
37. Qureshi, A., Kaur, G. and Kumar, M. (2017) AVCPred: an integrated web server for prediction and design of antiviral compounds. Chem. Biol. Drug Des., 89, 74–83.
38. Frank, E., Hall, M., Trigg, L., Holmes, G. and Witten, I.H. (2004) Data mining in bioinformatics using Weka. Bioinformatics, 20, 2479–2481.
39. Peng, H., Long, F. and Ding, C. (2005) Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans. Pattern Anal. Mach. Intell., 27, 1226–1238.
40. Rajput, A., Gupta, A.K. and Kumar, M. (2015) Prediction and analysis of quorum sensing peptides based on sequence features. PLoS One, 10, e0120066.
41. Krzywinski, M., Schein, J., Biro, J., Connors, J., Gascoyne, R., Horsman, D., Jones, S.J. and Marra, M.A. (2009) Circos: an information aesthetic for comparative genomics. Genome Res., 19, 1639–1645.
42. Rajput, A. and Kumar, M. (2017) Computational exploration of putative LuxR Solos in archaea and their functional implications in quorum sensing. Front. Microbiol., 8, 798.
43. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B. and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res., 13, 2498–2504.
44. Gutiérrez, M., Karwath, A. and Kramer, S. (2012) CheS-Mapper - chemical space mapping and visualization in 3D. J. Cheminform., 4, 7.
45. Qureshi, A., Thakur, N., Tandon, H. and Kumar, M. (2014) AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses. Nucleic Acids Res., 42, D1147–D1153.
46. Thakur, N., Qureshi, A. and Kumar, M. (2012) VlRsiRAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res., 40, D230–D236.
47. Bienfait, B. and Ertl, P. (2013) JSME: a free molecule editor in JavaScript. J. Cheminform., 5, 24.
48. Smith, A.S., Benson, J.E., Blaser, S.I., Mizushima, A., Tarr, R.W. and Bellon, E.M. (1991) Diagnosis of ruptured intracranial dermoid cyst: value MR over CT. AJNR Am. J. Neuroradiol., 12, 175–180.
49. Opperman, T.J., Kwaany, S.M., Williams, J.D., Khan, A.R., Peet, N.P., Moir, D.T. and Bowlin, T.L. (2009) Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation. Antimicrob. Agents Chemother., 53, 4357–4367.
50. Ta, C.A., Freudenthorfer, M., Mah, T.F., Otarola-Rojas, M., Garcia, M., Sanchez-Vindas, P., Poveda, L., Maschek, J.A., Baker, B.J., Adonizio, A.L. et al. (2014) Inhibition of bacterial quorum sensing and biofilm formation by extracts of neotropical rainforest plants. Planta Med., 80, 343–350.
51. Bruzual, I., Riggle, P., Hadley, S. and Kumamoto, C.A. (2007) Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole. J. Antimicrob. Chemother., 59, 441–450.
52. de Lima Pimenta, A., Chiaradia-Delatorre, L.D., Mascarello, A., de Oliveira, K.A., Leal, P.C., Yunes, R.A., de Aguiar, C.B., Tasca, C.I., Nunes, R.J. and Smania, A. Jr (2013) Synthetic organic compounds with potential for bacterial biofilm inhibition, a path for the identification of compounds interfering with quorum sensing. Int J Antimicrob Agents, 42, 519–523.
53. Sullivan, R., Santarpia, P., Lavender, S., Gittins, E., Liu, Z., Anderson, M.H., He, J., Shi, W. and Eckert, R. (2011) Clinical efficacy of a specifically targeted antimicrobial peptide mouth rinse: targeted elimination of Streptococcus mutans and prevention of demineralization. Caries Res., 45, 415–428.
54. Martinez, L.R. and Casadevall, A. (2006) Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect Immun., 74, 6118–6123.
55. Fair, R.J. and Tor, Y. (2014) Antibiotics and bacterial resistance in the 21st century. Perspect. Med. Chem., 6, 25–64.
56. Costerton, J.W., Stewart, P.S. and Greenberg, E.P. (1999) Bacterial biofilms: a common cause of persistent infections. Science, 284, 1318–1322.
57. Hoiby, N., Bjarnsholt, T., Givskov, M., Molin, S. and Ciofu, O. (2010) Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents, 35, 322–332.